AGX-148 is under clinical development by AgonOx and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AGX-148’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AGX-148 overview

AGX-148 is under development for the treatment of solid tumor, head and squamous cell carcinoma and metastatic melanoma. The therapy is an adoptive T cell therapy based on tumour infiltrating lymphocytes (TIL). It acts by targeting CD39, CD8, CD103. It is administered through intravenous route.

AgonOx overview

AgonOx is a pharmaceutical and healthcare company. The company offers biotechnology and clinical discovery solutions. It discovers and develops novel immunotherapy drugs targeting key regulators of the immune response to cancer. The company’s product includes AGX 051, AGX 141, AGX 149, AGX 509 and AGX 392, among others. AgonOx also designs and develop recombinant proteins, antibodiesor small molecules that block and activate novel immune-specific pathways and generate tumor-specific TIL to target tumors. AgonOx is headquartered in Portland, Oregon, the US.

For a complete picture of AGX-148’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.